VolitionRx (VNRX) Limited announced that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants. All of the securities in the offering are being offered by Volition. Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions. Newbridge Securities Corporation is acting as the sole book-running manager of the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX:
- Strategic Partnerships and Growth Potential Justify Buy Rating for VolitionRX
- VolitionRx signs co-marketing and services agreement with Hologic
- VolitionRX’s Strategic Partnership and Growth Potential Drive Buy Rating
- VolitionRx signs first human out licensing deal for APS
- VolitionRx Ltd. Earnings Call: Key Insights and Challenges